The Prevalence, Measurement, and Treatment of the Cognitive Dimension/Domain in Major Depressive Disorder

CNS Drugs

Volumn 29, Issue 7, 2015, Pages 577-589

  McIntyre, Roger S ^a,b,c   Xiao, Holly X ^c   Syeda, Kahlood ^c   Vinberg, Maj ^d   Carvalho, Andre F ^e   Mansur, Rodrigo B ^c   Maruschak, Nadia ^c   Cha, Danielle S ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ERYTHROPOIETIN; LISDEXAMFETAMINE; MODAFINIL; PSYCHOSTIMULANT AGENT; VORTIOXETINE; PSYCHOTROPIC AGENT;

AEROBIC EXERCISE; COGNITION; COGNITIVE DEFECT; CONCEPTUAL FRAMEWORK; DEFAULT MODE NETWORK; DSM-5; DSM-IV-TR; ELECTROCONVULSIVE THERAPY; EXECUTIVE FUNCTION; HUMAN; MAJOR DEPRESSION; MINI MENTAL STATE EXAMINATION; MONTREAL COGNITIVE ASSESSMENT; PATIENT HEALTH QUESTIONNAIRE 9; PREVALENCE; PRIORITY JOURNAL; REVIEW; SALIENCE NETWORK; SOCIAL COGNITION; COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; PATHOPHYSIOLOGY;

COGNITION DISORDERS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PREVALENCE; PSYCHOTROPIC DRUGS;

EID: 84940597033     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-015-0263-x     Document Type: Review

References (78)

1. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-105.
2. Vasiliadis HM, Lesage A, Adair C, Wang PS, Kessler RC. Do Canada and the United States differ in prevalence of depression and utilization of services? Psychiatr Serv. 2007;58(1):63-71.
3. Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE. Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety. 2010;27(1):78-89.
4. Collins PY, Insel TR, Chockalingam A, Daar A, Maddox YT. Grand challenges in global mental health: integration in research, policy, and practice. PLoS Med. 2013;10(4):e1001434.
5. Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, et al. Depression in the workplace: effects on short-term disability. Health Aff (Millwood). 1999;18(5):163-71.
6. Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-75.
7. Pratt LA, Brody DJ, Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief. 2011;76:1-8.
8. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28-40.
9. McIntyre RS. A vision for drug discovery and development: novel targets and multilateral partnerships. Adv Ther. 2014;31:245-6.
10. Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014;171(4):395-7.
11. Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov. 2012;11(2):141-68.
12. McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallaugher LA, Kudlow P, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30:515-27.
13. Roiser JP, Sahakian BJ. Hot and cold cognition in depression. CNS Spectr. 2013;18(3):139-49.
14. Pulcu E, Thomas EJ, Trotter PD, McFarquhar M, Juhasz G, Sahakian BJ, et al. Social-economical decision making in current and remitted major depression. Psychol Med. 2014;10:1-13.
15. Amft M, Bzdok D, Laird AR, Fox PT, Schilbach L, Eickhoff SB. Definition and characterization of an extended social-affective default network. Brain Struct Funct. 2015;220:1031-49.
16. Ladegaard N, Larsen ER, Videbech P, Lysaker PH. Higher-order social cognition in first-episode major depression. Psychiatry Res. 2014;216(1):37-43.
17. Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A, et al. Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry. 2009;166(10):1178-84.
18. Haddad AD, Williams JM, McTavish SF, Harmer CJ. Low-dose tryptophan depletion in recovered depressed women induces impairments in autobiographical memory specificity. Psychopharmacology (Berl). 2009;207(3):499-508.
19. Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, et al. The initial field trials of DSM-5: new blooms and old thorns. Am J Psychiatry. 2013;170(1):1-5.
20. Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res. 2006;145(1):39-48.
21. Conradi HJ, Ormel J, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study. Psychol Med. 2010;8:1-10.
22. Luo LL, Chen X, Chai Y, Li JH, Zhang M, Zhang JN. A distinct pattern of memory and attention deficiency in patients with depression. Chin Med J. 2013;126(6):1144-9.
23. Mandelli L, Serretti A, Colombo C, Florita M, Santoro A, Rossini D, et al. Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis. Psychiatry Clin Neurosci. 2006;60(5):598-604.
24. Zimmerman M, Posternak MA, Chelminski I. Using a self-report depression scale to identify remission in depressed outpatients. Am J Psychiatry. 2004;161(10):1911-3.
25. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D. How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry. 2006;163(1):148-50.
26. Papakostas GI. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J Clin Psychiatry. 2014;75(1):8-14.
27. Gualtieri CT, Morgan DW. The frequency of cognitive impairment in patients with anxiety, depression, and bipolar disorder: an unaccounted source of variance in clinical trials. J Clin Psychiatry. 2008;69(7):1122-30.
28. Samartzis L, Gavala E, Zoukos Y, Aspiotis A, Thomaides T. Perceived cognitive decline in multiple sclerosis impacts quality of life independently of depression. Rehabil Res Pract. 2014;2014:128751.
29. Thelen JM, Lynch SG, Bruce AS, Hancock LM, Bruce JM. Polypharmacy in multiple sclerosis: relationship with fatigue, perceived cognition, and objective cognitive performance. J Psychosom Res. 2014;76(5):400-4.
30. Airaksinen E, Wahlin A, Forsell Y, Larsson M. Low episodic memory performance as a premorbid marker of depression: evidence from a 3-year follow-up. Acta Psychiatr Scand. 2007;115(6):458-65.
31. Watters AJ, Gotlib IH, Harris AW, Boyce PM, Williams LM. Using multiple methods to characterize the phenotype of individuals with a family history of major depressive disorder. J Affect Disord. 2013;150(2):474-80.
32. van Oostrom I, Franke B, Arias VA, Rinck M, Tendolkar I, Verhagen M, et al. Never-depressed females with a family history of depression demonstrate affective bias. Psychiatry Res. 2013;205(1-2):54-8.
33. Christensen MV, Kyvik KO, Kessing LV. Cognitive function in unaffected twins discordant for affective disorder. Psychol Med. 2006;36(8):1119-29.
34. Martinez-Aran A, Vieta E, Colom F, Reinares M, Benabarre A, Gasto C, et al. Cognitive dysfunctions in bipolar disorder: evidence of neuropsychological disturbances. Psychother Psychosom. 2000;69(1):2-18.
35. Godard J, Baruch P, Grondin S, Lafleur MF. Psychosocial and neurocognitive functioning in unipolar and bipolar depression: a 12-month prospective study. Psychiatry Res. 2012;196(1):145-53.
36. Insel TR. Translating scientific opportunity into public health impact: a strategic plan for research on mental illness. Arch Gen Psychiatry. 2009;66(2):128-33.
37. Diamond PA. What stock market returns to expect for the future? Soc Secur Bull. 2000;2:38-52.
38. Baune BT, Miller R, McAfoose J, Johnson M, Quirk F, Mitchell D. The role of cognitive impairment in general functioning in major depression. Psychiatry Res. 2010;176(2-3):183-9.
39. Krishnan V, Nestler EJ. Linking molecules to mood: new insight into the biology of depression. Am J Psychiatry. 2010;167(11):1305-20.
40. Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci USA. 2003;100(1):253-8.
41. Uddin LQ, Kelly AM, Biswal BB, Xavier CF, Milham MP. Functional connectivity of default mode network components: correlation, anticorrelation, and causality. Hum Brain Mapp. 2009;30(2):625-37.
42. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E, Herrera-Abarca JE. Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on memory and mental processing speed in patients with major depressive disorder. J Psychiatr Res. 2009;43(9):855-63.
43. Herrera-Guzman I, Gudayol-Ferre E, Herrera-Abarca JE, Herrera-Guzman D, Montelongo-Pedraza P, Padros BF, et al. Major Depressive Disorder in recovery and neuropsychological functioning: effects of selective serotonin reuptake inhibitor and dual inhibitor depression treatments on residual cognitive deficits in patients with Major Depressive Disorder in recovery. J Affect Disord. 2010;123(1-3):341-50.
44. Lam R, Lonn S, Despiegel N. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis. Int Clin Psychopharmacol. 2010;25(4):199-203.
45. Borkowska A, Drozdz W, Ziolkowska-Kochan M, Rybakowski J. Enhancing effect of mirtazapine on cognitive functions associated with prefrontal cortex in patients with recurrent depression. Neuropsychopharmacol Hung. 2007;9(3):131-6.
46. Sasada K, Iwamoto K, Kawano N, Kohmura K, Yamamoto M, Aleksic B, et al. Effects of repeated dosing with mirtazapine, trazodone, or placebo on driving performance and cognitive function in healthy volunteers. Hum Psychopharmacol. 2013;28(3):281-6.
47. Ferguson JM, Wesnes KA, Schwartz GE. Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol. 2003;18(1):9-14.
48. Raskin J, Wiltse CG, Siegal A, Sheikh J, Xu J, Dinkel JJ, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry. 2007;164(6):900-9.
49. Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 2012;27(4):215-23.
50. McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 2014;30:1-11.
51. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults. Schizophr Bull. 2001;27(2):235-45.
52. Olsson AK, Helldin L, Hjarthag F, Norlander T. Psychometric properties of a performance-based measurement of functional capacity, the UCSD Performance-based Skills Assessment - brief version. Psychiatry Res. 2012;197(3):290-4.
53. Candy M, Jones L, Williams R, Tookman A, King M. Psychostimulants for depression. Cochrane Database Syst Rev. 2008;2:CD006722.
54. McIntyre RS, Filteau M-J, Martin L, Patry S, Carvalho A, Cha DS, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1-7.
55. Madhoo M, Keefe RSE, Roth RM, Sambunaris A, Wu J, Trivedi MH, et al. Lisdexamfetamine dimesylate augmentation in adults with persistent executive dysfunction after partial or full remission of major depressive disorder. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2014;39(6):1388-98.
56. Goss AJ, Kaser M, Costafreda SG, Sahakian BJ, Fu CHY. Modafinil augmentation therapy in unipolar and bipolar depression: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry. 2013;74(11):1101-7.
57. Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2008;33(7):1477-502.
58. Kelley AM, Webb CM, Athy JR, Ley S, Gaydos S. Cognition enhancement by modafinil: a meta-analysis. Aviat Space Environ Med. 2012;83(7):685-90.
59. Miskowiak KW, Vinberg M, Christensen EM, Bukh JD, Harmer CJ, Ehrenreich H, et al. Recombinant human erythropoietin for treating treatment-resistant depression: a double-blind, randomized, placebo-controlled phase 2 trial. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol. 2014;39(6):1399-408.
60. Solé B, Jiménez E, Martinez-Aran A, Vieta E. Cognition as a target in major depression: new developments. Eur Neuropsychopharmacol [Internet]; 2015. http://linkinghub.elsevier.com/retrieve/pii/S0924977X14003514. Cited 15 Feb 2015.
61. Liu CS, Carvalho AF, McIntyre RS. Towards a "metabolic" subtype of major depressive disorder: shared pathophysiological mechanisms may contribute to cognitive dysfunction. CNS Neurol Disord Drug Targets. 2014;13(10):1693-707.
62. Reger MA, Watson GS, Frey WH, Baker LD, Cholerton B, Keeling ML, et al. Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype. Neurobiol Aging. 2005;27(3):451-8.
63. McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, Macqueen G, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012;14(7):697-706.
64. Semkovska M, McLoughlin DM. Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis. Biol Psychiatry. 2010;68(6):568-77.
65. Bergfeld IO, Mantione M, Hoogendoorn ML, Denys D. Cognitive functioning in psychiatric disorders following deep brain stimulation. Brain Stimul. 2013;6(4):532-7.
66. Demirtas-Tatlidede A, Vahabzadeh-Hagh AM, Pascual-Leone A. Can noninvasive brain stimulation enhance cognition in neuropsychiatric disorders? Neuropharmacology. 2013;64:566-78.
67. Mammen G, Faulkner G. Physical activity and the prevention of depression: a systematic review of prospective studies. Am J Prev Med. 2013;45(5):649-57.
68. Cooney GM, Dwan K, Greig CA, Lawlor DA, Rimer J, Waugh FR, et al. Exercise for depression. Cochrane Database Syst Rev. 2013;9:CD004366.
69. Pei Z, Meng R, Zhuang Z, Zhao Y, Liu F, Zhu MZ, et al. Cardiac peroxisome proliferator-activated receptor-gamma expression is modulated by oxidative stress in acutely infrasound-exposed cardiomyocytes. Cardiovasc Toxicol. 2013;13(4):307-15.
70. Legrand FD. Effects of exercise on physical self-concept, global self-esteem, and depression in women of low socioeconomic status with elevated depressive symptoms. J Sport Exerc Psychol. 2014;36(4):357-65.
71. Rethorst CD, Sunderajan P, Greer TL, Grannemann BD, Nakonezny PA, Carmody TJ, et al. Does exercise improve self-reported sleep quality in non-remitted major depressive disorder? Psychol Med. 2013;43(4):699-709.
72. Rethorst CD, Toups MS, Greer TL, Nakonezny PA, Carmody TJ, Grannemann BD, et al. Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry. 2013;18(10):1119-24.
73. Trivedi MH, Greer TL, Church TS, Carmody TJ, Grannemann BD, Galper DI, et al. Exercise as an augmentation treatment for nonremitted major depressive disorder: a randomized, parallel dose comparison. J Clin Psychiatry. 2011;72(5):677-84.
74. Elgamal S, McKinnon MC, Ramakrishnan K, Joffe RT, Macqueen G. Successful computer-assisted cognitive remediation therapy in patients with unipolar depression: a proof of principle study. Psychol Med. 2007;37(9):1229-38.
75. Thorsen AL, Johansson K, Loberg EM. Neurobiology of cognitive remediation therapy for schizophrenia: a systematic review. Front Psychiatry. 2014;5:103.
76. Bowie CR, Gupta M, Holshausen K, Jokic R, Best M, Milev R. Cognitive remediation for treatment-resistant depression: effects on cognition and functioning and the role of online homework. J Nerv Ment Dis. 2013;201(8):680-5.
77. McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan MT, Cha DS, Carvalho AF, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015;56:279-82.
78. Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A randomized, placebo-controlled, active-referenced, double-blind, flexible-dose study of the efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 2015;40:2025-37.